CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer

Cui, Guoliang; Geng, Lanlan; Zhu, Li; Lin, Zhenyan; Liu, Xuan; Miao, Zhengyue; Jiang, Jintao; Feng, Xiaoke; Wei, Fei

doi:10.7150/jca.50832

Cited by 11 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies proposed that deficiency or pharmacological blockade of C5aR1 significantly impeded tumorigenesis of CRC, and the over-expression of C5aR1 contributed to the poor prognosis of CRC patients ( 40 , 41 ). CFP plays a positive role in regulating the natural immune system in alternative pathways, and it is associated with immune infiltration in gastric cancer and lung cancer ( 42 ). We speculated that CFP and CD55 might be involved in the immune infiltration of tumor cells in colon cancer.…”

Section: Discussionmentioning

confidence: 99%

The genetic and epigenetic regulation of CD55 and its pathway analysis in colon cancer

Liu

Yang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCD55 plays an important role in the development of colon cancer. This study aims to evaluate the expression of CD55 in colon cancer and discover how it is regulated by transcriptional factors and miRNA.MethodsThe expression of CD55 was explored by TIMER2.0, UALCAN, and Human Protein Atlas (HPA) databases. TRANSFAC and Contra v3 were used to predict the potential binding sites of transcription factors in the CD55 promoter. TargetScan and starBase v2.0 were used to predict the potential binding ability of miRNAs to the 3′ untranslated region (3′UTR) of CD55. SurvivalMeth was used to explore the differentially methylated sites in the CD55 promoter. Western blotting was used to detect the expression of TFCP2 and CD55. Dual-luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were performed to determine the targeting relationship of TFCP2, NF-κB, or miR-27a-3p with CD55. CD55-related genes were explored by constructing a protein–protein interaction (PPI) network and performing pathway analysis by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG).ResultsCD55 was highly expressed in colon cancer tissues. The mRNA and protein expression levels of TFCP2 were reduced by si-TFCP2. NF-κB mRNA was obviously reduced by NF-κB inhibitor and increased by NF-κB activator. CD55 protein was also inhibited by miR-27a-3p. Dual-luciferase reporter assays showed that after knocking down TFCP2 or inhibiting NF-κB, the promoter activity of CD55 was decreased by 21% and 70%, respectively; after activating NF-κB, the promoter activity of CD55 increased by 2.3 times. As TFCP2 or NF-κB binding site was mutated, the transcriptional activity of CD55 was significantly decreased. ChIP assay showed that TFCP2 and NF-κB combined to the promoter of CD55. The luciferase activity of CD55 3′UTR decreased after being co-transfected with miR-27a-3p mimics and increased by miR-27a-3p antagomir. As the miR-27a-3p binding site was mutated, we did not find any significant effect of miR-27a-3p on reporter activity. PPI network assay revealed a set of CD55-related genes, which included CFP, CFB, C4A, and C4B. GO and KEGG analyses revealed that the target genes occur more frequently in immune-related pathways.ConclusionOur results indicated that CD55 is regulated by TFCP2, NF-κB, miR-27a-3p, and several immune-related genes, which in turn affects colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The genetic and epigenetic regulation of CD55 and its pathway analysis in colon cancer

Liu

Yang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Then, we constructed the signature named SIRGs score through Cox regression analysis. Among them, CFP is a tumor prognostic marker associated with immune infiltration in gastric and lung cancer ( 34 ). ZDHHC11 can regulate the innate immune response to DNA viruses ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

BackgroundEsophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controversial.MethodsWe identified stromal immune-related genes (SIRGs) by ESTIMATE from the TCGA-EGJA dataset and constructed a signature score. In addition, survival analysis was performed in both the TCGA cohort and GEO cohort. Subsequently, we explored the differences in tumor-infiltrating immune cells, immune subtypes, immune-related functions, tumor mutation burden (TMB), immune checkpoint gene expression, immunophenoscore (IPS) between the high SIRGs score and low SIRGs score groups. Finally, two validation cohorts of patients who had accepted immunotherapy was used to verify the value of SIRGs score in predicting immunotherapy response.ResultsEight of the SIRGs were selected by LASSO regression to construct a signature score (SIRGs score). Univariate and multivariate analyses in the TCGA and GEO cohort suggested that SIRGs score was an independent risk factor for the overall survival (OS) and it could increase the accuracy of clinical prediction models for survival. However, in the high SIRGs score group, patients had more immune cell infiltration, more active immune-related functions, higher immune checkpoint gene expression and higher IPS-PD1 and IPS-PD1-CTLA4 scores, which indicate a better response to immunotherapy. The external validation illustrated that high SIRGs score was significantly associated with immunotherapy response and immune checkpoint inhibitors (ICIs) can improve OS in patients with high SIRGs score.ConclusionThe SIRGs score may be a predictor of the prognosis and immune-therapy response for esophagogastric junction adenocarcinoma.

show abstract

“…Tumor Immune Estimation Resource (TIMER) is an exhaustive resource database for researching the infiltration of immune cells in tumor tissues according to RNA sequencing data from kinds of tumors ( https://cistrome.shinyapps.io/timer/) [ 25 , 26 ]. The Routine analysis process is as Feng and Wei’s description [ 27 ]. The study of FNBP1 was performed by Diff Exp module, Gene module, Correlation module and Immune module.…”

Section: Methodsmentioning

confidence: 99%

“…The analysis methods were performed as described [ 27 ]. Put it simply, results generated in Oncomine are shown with P -values determined in t-tests, fold changes, and gene ranks.…”

Section: Methodsmentioning

confidence: 99%

Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD

Wang

Tian

et al. 2022

BMC Immunol

View full text Add to dashboard Cite

Background Formin-binding protein 1/17 (FNBP1/FBP17), as a membrane-bound protein, is wildly expressed in eukaryotic cells and performs a critical role in tumor tumorigenesis and progression. However, the relationship between FNBP1 and immune infiltrating cells, prognostic value in patients still require comprehensive understanding. We purposed to explore the correlations of FNBP1 expression, prognosis and immune infiltration levels in various cancers. Method The expression and survival data of FNBP1 were collected from Oncomine, TIMER, GEPIA, Kaplan–Meier Plotter and PrognoScan databases. Correlations between FNBP1 and immune infiltrates were analyzed in TIMER and GEPIA databases. Results Compared with normal tissues, FNBP1 is significantly differentially expressed in a variety of tumor tissues. FNBP1 has significant and complex effects on the prognosis of kinds of cancers. High-expression was obviously correlated with better prognosis in breast carcinoma and lung adenocarcinoma, while worse prognosis in stomach adenocarcinoma. Besides, FNBP1 had a correlation with various immune infiltrating cells and diverse immune gene markers in breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), and stomach adenocarcinoma (STAD). FNBP1 was also positively correlated with the adjustment of CD8+ cells, T cells, M2 macrophage, neutrophils, monocyte, Th1 cells, T regulatory cells (Treg) and Tumor-associated macrophages (TAMs). The expression level of FNBP1 is closely positively correlated with the expression level of multiple immune checkpoints in the three cancers. In addition, FNBP1 is significantly positively correlated with the expression levels of a variety of immunosuppressive molecules. Conclusion Our findings reveal FNBP1 can serve as a significant biomarker to influence the prognosis and the immune infiltrating levels in different cancers. The differential expression of FNBP1 might not only contribute to the judgment of metastatic and non-metastatic tumors but also in the immune escape by upregulating the expression of immune checkpoints.

show abstract

CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer

Cited by 11 publications

References 47 publications

The genetic and epigenetic regulation of CD55 and its pathway analysis in colon cancer

The genetic and epigenetic regulation of CD55 and its pathway analysis in colon cancer

SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma

Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD

Contact Info

Product

Resources

About